Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.
C-US-PWS-00066
Shared 1 year ago
3.5K views
Shared 1 year ago
195 views
Shared 1 year ago
78 views
Shared 1 year ago
138 views
Shared 1 year ago
2.9K views
Shared 1 year ago
404 views
Shared 2 years ago
836 views
Shared 2 years ago
277 views